How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope for.

Key outcomes of all-cause mortality and portal hypertension complications are improved with SGLT2inhibitors, new research ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Wegovy, a highly effective medication used to treat obesity, shows promise in treating a serious form of liver disease in a ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.

In the 10-Q report, 89bio detailed its progress in the development of pegozafermin, particularly in its Phase 3 clinical ...

So, there's this scientist, Arun Sanyal, M.D., who's the director of the VCU Stravitz-Sanyal Institute for Liver Disease and ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...